摘要
目的探究恩替卡韦在肺结核合并慢性乙型肝炎患者中的疗效。方法盲选本院收治的肺结核合并慢性乙型肝炎患者108例,分两组,各54例,对照组采用常规治疗,试验组在对照组的基础上增加施恩替卡韦治疗,比较两组治疗效果。结果治疗前,比较两组各项临床指标,没有明显差异(P>0.05);治疗后,试验组TBIL、ALT、GGT、ALB、AST及HBV-DNA临床指标分别是(4.9±4.3)μmol/L、(67.58±25.89)U/L、(165.6±12.2)U/L、(60.3±26.7)g/L、(36.61±3.01)U/L、(1.00±0.34)×10^(3)copies/mL,显著优于对照组(12.5±4.6)μmol/L、(95.37±25.29)U/L、(170.8±11.9)U/L、(50.0±25.4)g/L、(30.02±3.06)U/L、(1.54±0.56)×10^(3)copies/mL(P<0.05)。试验组临床治疗总有效率98.15%(53/54),远高于对照组77.78%(42/54)(P<0.05)。结论对肺结核合并慢性乙型肝炎患者在常规治疗的基础上采用恩替卡韦治疗,临床疗效显著,建议推广。
Objective To explore the therapeutic effect of entecavir in patients with pulmonary tuberculosis complicated with chronic hepatitis B.Methods One hundred and eight patients with pulmonary tuberculosis complicated with chronic hepatitis B admitted to our hospital were randomly divided into two groups,54 cases in each group.The control group was treated with conventional therapy,while the experimental group was treated with entecavir on the basis of conventional therapy.The therapeutic effects of the two groups were compared.Results Before treatment,there was no significant difference in clinical indexes between the two groups(P>0.05).After treatment,the clinical indexes of TBIL,ALT,GGT,ALB,AST and HBV-DNA in the experimental group were(4.9±4.3)μmol/L,(67.58±25.89)U/L,(165.6±12.2)U/L,(60.3±26.7)g/L,(36.61±3.01)U/L,(1.00±0.34)×10^(3) copies/mL,respectively.It is significantly better than the control group(12.5±4.6)μmol/L,(95.37±25.29)U/L,(170.8±11.9)U/L,(50.0±25.4)g/L,(30.02±3.06)U/L,(1.54±0.56)×10^(3) copies/mL(P<0.05).The total effective rate of clinical treatment in the experimental group was 98.15%(53/54),far higher than 77.78%(42/54)in the control group(P<0.05).Conclusion On the basis of conventional treatment,entecavir is used in the treatment of pulmonary tuberculosis patients with chronic hepatitis B.The clinical effect is significant,and it is recommended to be popularized.
作者
刘施佳
LIU Shijia(Fuxin Infectious Disease Hospital,Fuxin 123000,China)
出处
《中国医药指南》
2021年第7期20-21,共2页
Guide of China Medicine
